Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

45.96USD
29 Aug 2014
Price Change (% chg)

$0.29 (+0.63%)
Prev Close
$45.67
Open
$45.77
Day's High
$46.00
Day's Low
$45.67
Volume
147,564
Avg. Vol
150,970
52-wk High
$48.42
52-wk Low
$32.21

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.97
Market Cap (Mil.): $96,800.31
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.81

Financials

  NVO.N Industry Sector
P/E (TTM): 26.72 32.30 33.23
EPS (TTM): 1.72 -- --
ROI: 65.79 17.96 17.21
ROE: 71.98 18.60 18.01
Search Stocks

BRIEF-Novo Nordisk buys production plant in New Hampshire

Aug 27 - Novo Nordisk A/S says: ** Has announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech. ** Intends to use the facility for production of active pharmaceutical ingredients ** Has agreed not to disclose the terms of the acquisition

27 Aug 2014

Denmark's Novo Nordisk accepts fine for late disclosure of drug setback

COPENHAGEN, Aug 18 - Novo Nordisk A/S said on Monday it had accepted a near $90,000 fine from Danish regulators for failing to inform investors quickly enough that a drug it had hoped would become its next growth driver had been refused U.S. approval.

18 Aug 2014

Novo Nordisk aims for 2016 Tresiba launch in U.S

COPENHAGEN - Novo Nordisk <NOVOb.CO said on Thursday it could launch its new long-acting insulin Tresiba, a crucial future growth driver for the Danish company, at the start of 2016 in the United States.

07 Aug 2014

UPDATE 2-Novo Nordisk aims for 2016 Tresiba launch in U.S.

* Shares up 1.5 pct (Adds comments from CEO, analysts, share price)

07 Aug 2014

Novo Nordisk says FDA approval for Tresiba could come end-2015

COPENHAGEN, Aug 7 - Novo Nordisk could receive an approval from the U.S. Food and Drug Administration for Tresiba by the end of next year, paving the way for its launch in the United States at the start of 2016, the company's chief executive said on Thursday.

07 Aug 2014

NORDIC STOCKS - Factors to watch on Aug 7

HELSINKI, Aug 7 - The following stocks may be affected by newspaper reports and other factors on Thursday:

07 Aug 2014

Novo Nordisk results in line with expectations, keeps outlook

COPENHAGEN, Aug 7 - Denmark's Novo Nordisk , the world's top maker of insulin, posted on Thursday second-quarter operating profit in line with forecasts and maintained its operating profit and sales growth outlook.

07 Aug 2014

Novo Nordisk results in line with expectations, keeps outlook

COPENHAGEN, Aug 7 - Denmark's Novo Nordisk , the world's top maker of insulin, posted on Thursday second-quarter operating profit in line with forecasts and maintained its operating profit and sales growth outlook.

07 Aug 2014

NORDIC STOCKS - Factors to watch on Aug 7

HELSINKI, Aug 7 - The following stocks may be affected by newspaper reports and other factors on Thursday:

07 Aug 2014

Novo wins EU recommendation for two-in-one diabetes drug

LONDON - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

25 Jul 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €83.50 +1.03
Eli Lilly and Co (LLY.N) $63.56 +0.45

Earnings vs. Estimates

Search Stocks